Date: 2015-07-20
Type of information: Private placement
Company: DBV Technologies (France)
Investors:
Amount: $281.5 million
Funding type: private placement
Planned used:
Others: * On July 20, 2015, DBV Technologies announced the closing of its previously announced underwritten public offering of 4,140,000 ordinary shares in the form of 8,280,000 American Depositary Shares at a price to the public of $34.00 per ADS, which included an additional 1,080,000 ADSs sold pursuant to the full exercise of the underwriters\' option to purchase additional ADSs. The Company received gross proceeds from the offering of approximately $281.5 million, before underwriting discounts and commissions. All of the ADSs were offered by DBV Technologies. Each ADS represents the right to receive one-half of one ordinary share. The ADSs are listed on the Nasdaq Global Select Market under the symbol “DBVT,” and the Company’s ordinary shares are listed on Euronext Paris under the symbol “DBV.” Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc. and Leerink Partners LLC acted as the joint book-running managers for the offering. H.C. Wainwright & Co. acted as comanager for the offering and Bryan, Garnier & Co. acted as financial advisor to the Company in connection with the offering. * On July 15, 2015, DBV Technologies announced the pricing of an underwritten public offering of 3,600,000 ordinary shares in the form of 7,200,000 American Depositary Shares, or ADSs, at a price to the public of $34.00 per ADS, before underwriting discounts and commissions. Each ADS represents the right to receive one-half of one ordinary share. The gross proceeds to the Company from the offering are expected to be $244.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase additional ordinary shares in the form of 1,080,000 ADSs. * On July 14, 2015, DBV Technologies announced that it intends to offer and sell 6,000,000 American Depositary Shares, or ADSs, representing 3,000,000 ordinary shares, in an underwritten public offering in the United States. The Company intends to grant the underwriters a 30-day option to purchase 450,000 additional ordinary shares in the form of 900,000 ADSs. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The price per ADS at which ADSs will be sold in the proposed offering will be determined following a bookbuilding process and shall not be less than the volume weighted-average of closing price of the Company’s ordinary shares on the Euronext Paris over the three days prior to commencement of marketing of the proposed offering, possibly decreased by a maximum discount of 5%. * On July 2, 2015, DBV Technologies announced that it has filed a registration statement on Form F-1 with the U.S Securities and Exchange Commission (SEC) for a proposed underwritten public offering of ordinary shares in the form of American Depositary Shares (ADS). This offering will be subject to the registration statement on Form F-1 becoming effective. The Company has also filed a prospectus with the Autorités des Marchés Financiers and intends to request a visa with respect to the admission of the new ordinary shares underlying the ADSs on the regulated market of Euronext in Paris. DBV Technologies intends to issue the new securities within the limits of the authorizations granted at the Company’s General Meeting held on June 23, 2015, such that a maximum of 30% of the Company’s share capital will be issued in the proposed offering at an offering price not less than the volume weighted-average of closing price of the Company’s ordinary shares on the Euronext Paris over the three days prior to commencement of marketing of the proposed offering, possibly decreased by a maximum discount of 5%.
Therapeutic area: Allergic diseases
